Mitochondria, Inflammation, and the Ancient Bacterial Blueprint

More than two billion years ago, a free-living bacterium was engulfed by a larger cell and, rather than being digested, established a permanent partnership. That event, endosymbiosis, gave rise to the mitochondrion. Today every one of the roughly 37 trillion cells in the human body carries descendants of that ancient microbe, and the bacterial origins of mitochondria have never been fully erased. They persist in the mitochondrial genome, in the structure of mitochondrial membranes, and, most consequentially for human health and longevity, in the way the immune system responds when mitochondria are stressed or damaged. Understanding the mitochondria inflammation mechanism, the molecular chain of events by which distressed mitochondria trigger the innate immune system, is now recognized as one of the most important frontiers in longevity medicine.

Chronic, low-grade inflammation that persists without an identifiable infection, what geroscientists call inflammaging, predicts virtually every major age-related disease: cardiovascular disease, type 2 diabetes, neurodegeneration, cancer, and frailty. For decades the dominant explanation pointed to accumulated cellular debris, senescent cells, and gut barrier dysfunction. Those mechanisms are real, but they do not fully account for why inflammation rises so reliably with age. A growing body of evidence points toward the mitochondrion as a central instigator, a cellular power plant that, as it degrades over decades, begins leaking molecular signals that the immune system reads as a bacterial invasion. The logic is elegant and, once understood, changes how one thinks about aging itself.

A Bacterium Inside Every Cell: The Endosymbiotic Legacy

The endosymbiotic theory, proposed by Lynn Margulis in 1967 and now supported by overwhelming genomic evidence, holds that mitochondria descended from an ancient alphaproteobacterium related to today's Rickettsiales [1]. Over evolutionary time, most of the ancestral bacterial genome was either discarded or transferred to the host cell's nucleus, a process called endosymbiotic gene transfer. What remained is the mitochondrial genome: in humans, a circular, 16,569-base-pair loop of DNA encoding just 37 genes, replicated not by the machinery of eukaryotic chromosomes but by proteins that closely resemble those of gram-negative bacteria [2].

This circular architecture matters far beyond molecular biology. Bacterial DNA is recognized by the mammalian innate immune system as a danger signal. The key sensor is a cytosolic protein called cGAS, cyclic GMP-AMP synthase, which functions like a molecular tripwire. When cGAS encounters double-stranded DNA in the cytoplasm, it synthesizes the second messenger cGAMP, which activates a downstream protein called STING, the stimulator of interferon genes. STING then triggers a cascade that culminates in the production of type I interferons and pro-inflammatory cytokines [3]. Under normal circumstances, cytoplasmic DNA means one thing: infection. Mitochondrial DNA, with its bacterial structure including unmethylated CpG motifs, is chemically indistinguishable from bacterial DNA. The immune system did not evolve to distinguish between the two.

Mitochondrial DNA is chemically indistinguishable from bacterial DNA. The immune system did not evolve to tell them apart.

For most of early life, the immune system never sees mitochondrial DNA because healthy mitochondria are sealed within two concentric membranes. But that physical containment is the critical assumption, and it is one that aging systematically undermines. As mitochondria accumulate damage over decades, their membrane integrity falters. When it does, the ancient bacterial blueprint they carry becomes a trigger for the very inflammatory response it was meant to evade. This is not a design flaw. It is an evolutionary inheritance with profound consequences for how humans age.

From Powerhouse to Alarm System: How Mitochondrial Stress Initiates Inflammation

The classical view of mitochondria as cellular power plants, churning out adenosine triphosphate through oxidative phosphorylation, has given way to a richer picture. Mitochondria are now understood as signaling hubs, constantly sampling the metabolic and stress state of the cell and broadcasting that information through multiple molecular channels. Several of these channels feed directly into inflammatory pathways, and they become increasingly active as mitochondrial function declines with age.

The first channel is reactive oxygen species, or ROS. Oxidative phosphorylation works like a controlled electrochemical waterfall: electrons cascade down a series of protein complexes embedded in the inner mitochondrial membrane, ultimately combining with oxygen to form water. When the electron transport chain is efficient, very little leaks out. When it is damaged or overwhelmed, electrons escape and react with oxygen to form superoxide and hydrogen peroxide. These molecules are not simply toxic byproducts. At low concentrations they serve as signals. At chronically elevated concentrations, which is the state of aged or dysfunctional mitochondria, they oxidize lipids, proteins, and DNA. Oxidized mitochondrial DNA released into the cytoplasm is especially potent activator of the NLRP3 inflammasome, a multiprotein complex that cleaves pro-interleukin-1β into its active, highly inflammatory form [4]. The NLRP3 inflammasome has been found activated in macrophages, neurons, endothelial cells, and cardiomyocytes of aged animals, linking mitochondrial ROS directly to tissue-level inflammation across multiple organ systems.

The second channel runs through the outer mitochondrial membrane and involves proteins called cardiolipin and N-formyl peptides. Cardiolipin is a phospholipid found almost exclusively in bacteria and in the inner mitochondrial membrane, another molecular remnant of the endosymbiotic ancestor. When mitochondria are damaged, cardiolipin migrates to the outer membrane surface, where it acts as an eat-me signal for selective autophagy, but also as a direct activator of the NLRP3 inflammasome [4]. N-formyl peptides, short protein fragments beginning with a formylmethionine residue, are another bacterial signature: bacteria initiate translation with a formylated methionine, and so do mitochondria. When mitochondria rupture, these peptides spill into the cytoplasm and bloodstream, where they bind formyl peptide receptors on neutrophils and macrophages, triggering chemotaxis and cytokine release just as a bacterial peptide would [5].

The third and perhaps most systemically consequential channel is the release of mitochondrial DNA itself into the cytoplasm or extracellular space. This can occur through at least three routes: rupture of damaged mitochondria, extrusion through mitochondrial permeability transition pores, and selective packaging into extracellular vesicles. Once in the cytoplasm, mitochondrial DNA activates not only the cGAS-STING pathway but also toll-like receptor 9 on endosomes, a receptor originally characterized as a detector of bacterial and viral DNA [6]. Circulating mitochondrial DNA in plasma has been detected in aged individuals at concentrations that correlate with levels of C-reactive protein and interleukin-6, two canonical markers of systemic inflammation [7]. The mitochondrion is broadcasting its own distress in a language the immune system was evolved to read as danger.

The cGAS-STING Axis: Ancient Antiviral Defense Turned Against the Aging Self

The cGAS-STING pathway deserves particular attention because it sits at the intersection of mitochondrial biology, innate immunity, and aging in a way that is only beginning to be therapeutically exploited. cGAS was first characterized as a sensor of cytosolic DNA in the context of viral infection, and STING inhibition became a target in autoimmune disease research. Only in the past decade has it become clear that this pathway is also a core driver of the sterile inflammation that characterizes aging.

In aged cells, mitochondrial DNA escapes into the cytoplasm through two primary mechanisms. First, defective mitophagy, the selective autophagy pathway that normally clears damaged mitochondria before they can leak their contents, allows dysfunctional organelles to accumulate and eventually rupture. Second, age-associated loss of mitochondrial membrane potential drives the formation of macropores in the outer mitochondrial membrane through a process involving BAX and BAK proteins, the same proteins that orchestrate apoptosis. These pores are large enough to permit mitochondrial DNA herniation without triggering full cell death, creating a situation where the cell continues to live and function while continuously leaking immunostimulatory DNA [8].

Aged cells can continuously leak immunostimulatory DNA without dying, creating a permanent low-grade alarm state that reshapes tissue function over decades.

Once cGAS-STING is activated by cytoplasmic mitochondrial DNA, the transcriptional output is broad. NF-κB, the master regulator of inflammation, is activated. IRF3, a transcription factor for type I interferons, is activated. Both produce cytokines, including TNF-α, IL-6, IL-1β, and interferon-β, that circulate systemically and alter immune cell behavior throughout the body. In the context of a genuine bacterial infection, this response is lifesaving. In the context of a 70-year-old's chronically leaking mitochondria, it becomes the substrate for inflammaging. Studies in mice with genetic deletion of cGAS or STING show reduced inflammaging markers and, in some models, extended healthspan, providing causal evidence that this pathway is not merely associated with aging but mechanistically drives it [8].

Senescent cells, those cells that have permanently exited the cell cycle and adopted the pro-inflammatory secretory phenotype known as SASP, are particularly active cGAS-STING activators. Senescent cells frequently display cytoplasmic chromatin fragments and dysfunctional mitochondria, creating a self-reinforcing loop: mitochondrial dysfunction drives senescence, senescent cells produce more mitochondrial dysfunction, and both feed the cGAS-STING pathway. This convergence helps explain why therapies that reduce the senescent cell burden, senolytics, also reduce systemic mitochondrial stress markers, even though they target a seemingly different cellular population [9].

Mitophagy as the Off Switch: When Clearance Fails, Inflammation Persists

If mitochondrial damage and leakage drive inflammation, then the system that clears damaged mitochondria before they can leak should be understood as an anti-inflammatory mechanism. Mitophagy is that system. It is a selective form of autophagy, the cellular recycling process, in which damaged mitochondria are tagged, engulfed by a double-membrane vesicle called an autophagosome, and delivered to lysosomes for degradation. The two best-characterized mitophagy pathways are PINK1-Parkin, named for proteins mutated in familial Parkinson's disease, and BNIP3L/NIX-dependent mitophagy, which operates during hypoxia and red blood cell maturation.

In the PINK1-Parkin pathway, healthy mitochondria continuously import and degrade the kinase PINK1, keeping its cytoplasmic levels low. When the mitochondrial membrane potential collapses, a sign of serious damage, PINK1 accumulates on the outer membrane, recruits the E3 ubiquitin ligase Parkin, and initiates a cascade of ubiquitination that marks the mitochondrion for autophagosomal engulfment. Think of it as a quality-control inspector that tags defective units for removal before they cause problems on the factory floor. The efficiency of this system declines with age, and the decline correlates precisely with the accumulation of dysfunctional mitochondria and rising inflammatory markers [10].

The connection between mitophagy failure and the cGAS-STING pathway is direct. When PINK1 or Parkin are genetically deleted in mice, cytoplasmic mitochondrial DNA accumulates, cGAS-STING is constitutively activated, and the animals develop a sterile inflammatory syndrome. Conversely, pharmacological or genetic enhancement of mitophagy reduces cytoplasmic mitochondrial DNA and attenuates cGAS-STING signaling [9]. This relationship places mitophagy not merely as a housekeeping function but as a critical regulator of systemic immune tone. Compounds that enhance mitophagy, including urolithin A, a gut-derived metabolite of polyphenols found in pomegranates and berries, and spermidine, a polyamine found in wheat germ, have been shown to reduce inflammatory markers in aged animals and in early human trials [11]. The therapeutic logic is clear: restore mitophagy, reduce mitochondrial DNA leakage, quiet the cGAS-STING alarm.

Tissue-Specific Consequences: Inflammation Routed Through Different Organs

The mitochondria inflammation mechanism does not operate identically in every tissue. The consequences of mitochondrial damage-driven inflammation are shaped by which cell types harbor the most dysfunctional mitochondria and which tissues are most sensitive to the resulting cytokine environment. Three organ systems illustrate the stakes most clearly: the brain, the heart, and skeletal muscle.

In the brain, neurons are among the most energetically demanding cells in the body, consuming roughly 20 times more ATP per unit mass than a resting skeletal muscle fiber. Their dependence on oxidative phosphorylation makes them acutely vulnerable to mitochondrial dysfunction. But the more consequential problem may be in microglia, the brain's resident immune cells. Microglia express high levels of cGAS, STING, NLRP3, and toll-like receptor 9. When they encounter mitochondrial DNA, whether released from nearby neurons or arriving via the bloodstream, they enter an activated state characterized by secretion of IL-1β, TNF-α, and IL-18. This neuroinflammatory profile is found consistently in post-mortem brain tissue from patients with Alzheimer's disease, Parkinson's disease, and multiple sclerosis [12]. In Parkinson's disease, the connection is especially stark: mutations in PINK1 and Parkin, two core mitophagy proteins, are the most common causes of familial Parkinson's disease, and Parkinson's pathology is associated with elevated circulating mitochondrial DNA and constitutive NLRP3 inflammasome activation in brain tissue [13].

In the heart, cardiomyocytes, the contractile cells that beat roughly 100,000 times per day, have an extraordinarily high mitochondrial density, with mitochondria comprising up to 35% of cardiomyocyte volume. Age-related decline in mitochondrial quality in cardiomyocytes activates the NLRP3 inflammasome and cGAS-STING pathway, contributing to the fibrosis and diastolic dysfunction characteristic of the aging heart. Plasma mitochondrial DNA levels in patients with heart failure are approximately twice those in age-matched healthy controls and correlate with disease severity and inflammatory biomarker levels [14]. The clinical implication is that the chronic low-grade inflammation driving cardiovascular aging is not merely a consequence of plaques or metabolic dysregulation; it is also a consequence of cardiomyocytes slowly leaking their ancient bacterial inheritance.

In skeletal muscle, sarcopenia, the progressive loss of muscle mass and strength that begins in the fourth decade of life, is associated with a distinct pattern of mitochondrial dysfunction. Aged muscle fibers show reduced mitochondrial biogenesis, impaired electron transport chain efficiency, and accumulation of mitochondria harboring deletions in their circular genomes. The resulting increase in local ROS and cytokine production creates a catabolic environment that accelerates the very muscle loss it is associated with, because pro-inflammatory cytokines like TNF-α and IL-6 directly inhibit muscle protein synthesis and activate atrophy-promoting pathways [15]. Exercise, particularly resistance and high-intensity interval training, is the most potent known stimulus for mitochondrial biogenesis and mitophagy in skeletal muscle, which partly explains its anti-inflammatory effects and its protective role against sarcopenia.

Metabolic Crosstalk: How Insulin Resistance and Mitochondrial Inflammation Amplify Each Other

Metabolic dysfunction and mitochondrial inflammation are not parallel processes. They are interlocked in a feedback loop that accelerates both trajectories. Insulin resistance, the cellular failure to respond normally to insulin, is associated with impaired mitochondrial function in skeletal muscle, liver, and adipose tissue. But the relationship runs in both directions: mitochondrial inflammation drives insulin resistance through several mechanisms, including JNK and IKKβ activation by mitochondrial ROS, which phosphorylate insulin receptor substrate proteins and impair downstream insulin signaling [16].

The adipose tissue connection is particularly important. Visceral adipocytes store large amounts of energy but have relatively modest mitochondrial density. As adipocytes expand in obesity, their mitochondria become increasingly dysfunctional, their capacity to oxidize fatty acids declines, and they begin releasing mitochondrial DNA and N-formyl peptides into the interstitial space. Adipose-resident macrophages, called M1-polarized macrophages in inflammatory conditions, detect these signals through toll-like receptor 9 and NLRP3, producing the IL-6 and TNF-α that drive systemic insulin resistance [17]. Reducing adiposity, whether through caloric restriction, GLP-1 receptor agonist therapy such as programs available through GLP-1 Longevity Care, or surgical means, reduces circulating mitochondrial DNA and attenuates adipose tissue inflammation, suggesting that the mitochondrial inflammation mechanism is partly responsible for the metabolic benefits of weight loss.

SGLT2 inhibitors, a class of glucose-lowering agents that block renal glucose reabsorption, have demonstrated surprising cardioprotective and renoprotective benefits that extend well beyond their glucose-lowering effect. Emerging evidence suggests part of this benefit operates through mitochondrial pathways: SGLT2 inhibitors reduce NLRP3 inflammasome activation, reduce mitochondrial ROS production, and improve mitochondrial membrane potential in cardiomyocytes and renal tubular cells [18]. Healthspan's SGLT2 Protocol is designed for metabolically complex patients where these mitochondrial anti-inflammatory effects may contribute meaningfully to long-term organ protection. Metformin, another longevity-associated compound available through Metformin programs, has been shown to activate AMPK and modestly reduce mitochondrial complex I activity, lowering ROS production and downstream inflammatory signaling in aged tissues [19].

mTOR, Autophagy, and the Regulatory Architecture Above Mitophagy

Mitophagy does not operate in isolation. It is embedded within a broader regulatory network controlled primarily by two master sensors: mTOR, the mechanistic target of rapamycin, and AMPK, AMP-activated protein kinase. These two kinases function as opposing sensors of cellular energy status. AMPK is activated when energy is scarce, as in fasting or exercise. mTOR complex 1 is activated when nutrients and growth signals are abundant. The two kinases directly regulate autophagy, including mitophagy, in a reciprocal fashion: AMPK promotes it and mTOR suppresses it.

Chronic mTOR hyperactivation, which occurs in the context of persistent nutrient surplus, obesity, and aging itself, suppresses autophagy and mitophagy, allowing damaged mitochondria to accumulate. This creates a direct mechanistic link between dietary patterns, mTOR activity, mitophagy efficiency, mitochondrial DNA leakage, and systemic inflammation. The relevance for longevity is substantial. Rapamycin, the mTOR inhibitor that has demonstrated lifespan extension in every mammalian species tested to date, reduces inflammaging markers partly through restoring mitophagy [20]. By suppressing mTOR, rapamycin releases the brake on autophagy, allowing cells to clear the dysfunctional mitochondria that are leaking inflammatory signals. Healthspan's The Rapamycin Protocol is supervised precisely because the dose-timing relationship determines whether one gets the mitophagy-enhancing benefit or the immunosuppressive risk, a distinction that matters enormously in long-term use.

Rapamycin extends lifespan in every mammalian model tested. Part of its mechanism runs directly through restored mitophagy and quieted mitochondrial inflammatory signaling.

AMPK activation offers a complementary approach. Metformin is a mild AMPK activator. Exercise activates AMPK acutely and, with regular training, improves the baseline mitophagy capacity of skeletal muscle. Caloric restriction and intermittent fasting do so through combined AMPK activation and mTOR suppression. These lifestyle-based interventions converge on the same mitophagy-promoting effect, and their anti-inflammatory consequences can now be understood mechanistically rather than empirically. They are not merely reducing calories; they are restoring a clearance system that keeps mitochondria from broadcasting a false bacterial alarm.

Long COVID, Sepsis, and Acute Mitochondrial DNA Release

The mitochondria inflammation mechanism is not only a slow story of aging. It also operates in acute and post-acute disease states, most dramatically illustrated by sepsis and long COVID. In sepsis, bacterial infection triggers massive mitochondrial damage in multiple organ systems simultaneously. The resulting acute release of mitochondrial DNA into the bloodstream amplifies the innate immune response beyond what the bacterial pathogen alone would produce, contributing to the cytokine storm and multi-organ failure that make sepsis so lethal. Plasma mitochondrial DNA levels in septic patients are 100 to 1000-fold higher than in healthy controls and are independently associated with 28-day mortality [21].

In long COVID, a syndrome characterized by fatigue, cognitive impairment, and immune dysregulation persisting more than 12 weeks after acute SARS-CoV-2 infection, converging evidence points to persistent mitochondrial dysfunction as a core pathophysiological mechanism. SARS-CoV-2 proteins directly interfere with mitochondrial membrane integrity and suppress mitophagy, allowing damaged mitochondria to accumulate in multiple tissues. Post-mortem and biopsy studies show that patients with long COVID exhibit elevated cytoplasmic mitochondrial DNA, constitutive cGAS-STING activation, and elevated NLRP3 inflammasome activity in immune cells that persist well beyond viral clearance [22]. The mitochondria inflammation mechanism, in this context, is not a background process but a foregrounded one, driving the very symptoms that define long COVID: fatigue from impaired energy production, cognitive fog from neuroinflammation, and immune dysregulation from persistent type I interferon signaling.

Therapeutic Implications: Quieting the Ancient Alarm

The mechanistic clarity of the mitochondria inflammation pathway opens several therapeutic angles, some established, some emerging, and some still speculative. Placing them in appropriate epistemic categories is essential for honest clinical discussion.

The most established intervention remains exercise. Endurance and resistance training increase mitochondrial biogenesis through PGC-1α activation, improve electron transport chain efficiency, enhance mitophagy through AMPK and PINK1-Parkin upregulation, and reduce baseline ROS production in skeletal muscle. The anti-inflammatory effect of regular exercise is measurable, with reductions in IL-6, TNF-α, and C-reactive protein observed across dozens of randomized controlled trials in aging populations. These effects are now interpretable as direct consequences of improved mitochondrial quality control and reduced mitochondrial DNA leakage, not merely improved metabolic health [23].

Emerging interventions include molecules that specifically enhance mitophagy or reduce NLRP3 and cGAS-STING activation. Urolithin A, produced by gut bacteria from ellagitannins in pomegranates, walnuts, and berries, is the best-characterized natural mitophagy inducer in humans. A randomized controlled trial in older adults showed that urolithin A supplementation improved mitochondrial gene expression in skeletal muscle and reduced plasma inflammatory markers after four weeks of use [11]. Spermidine, NAD+ precursors such as NMN and NR, which restore SIRT1 and SIRT3 deacetylase activity to enhance mitochondrial quality, and low-dose lithium are all under investigation as mitophagy-enhancing agents, though the human clinical evidence remains early for most.

Methylene blue occupies an intriguing position in this landscape. As an electron carrier capable of bypassing damaged segments of the mitochondrial electron transport chain, it can partially restore oxidative phosphorylation in dysfunctional mitochondria, reducing electron leakage and ROS production. Preclinical studies suggest it reduces mitochondrial ROS and downstream inflammatory signaling in neuronal models, and Healthspan's Methylene Blue program is designed for supervised use in appropriate patients. The evidence base is promising but not yet at the level of randomized controlled trials in humans for the specific endpoint of mitochondrial inflammation.

The cGAS-STING pathway itself is now a pharmaceutical target. Multiple small-molecule STING antagonists are in early clinical trials for autoimmune diseases, and the same logic applies to inflammaging: if the pathway is chronically activated by mitochondrial DNA in aged tissues, selective inhibition could reduce systemic inflammation without impairing the pathway's appropriate response to genuine infections. This therapeutic niche requires exquisite dose precision, and it remains to be seen whether partial STING inhibition can quiet the mitochondrial alarm without opening the door to increased infection susceptibility.

Hormone optimization has an underappreciated relationship with mitochondrial function. Estradiol enhances mitochondrial biogenesis and reduces mitochondrial ROS production in multiple tissues, including the brain and cardiovascular system, through estrogen receptor-mediated upregulation of PGC-1α and antioxidant enzymes. Testosterone similarly supports mitochondrial biogenesis and electron transport chain efficiency in skeletal muscle and cardiac tissue. The decline in both hormones with aging contributes to the mitochondrial dysfunction trajectory, and hormone replacement protocols, such as those offered through Women's Hormone Health and Men's Hormone Health at Healthspan, may partially attenuate the mitochondrial inflammation mechanism in addition to their well-established symptomatic and structural benefits.

The Evolutionary Paradox and Its Clinical Resolution

There is a paradox at the heart of this story. The mitochondria inflammation mechanism, the tendency of damaged mitochondria to trigger innate immune responses through their bacterial molecular signatures, appears destructive. Yet it was never selected against in evolution because it primarily manifests in post-reproductive life, after the period during which natural selection operates most strongly. What might have once served as a safeguard, an immune response triggered by catastrophically damaged cells to promote their clearance, becomes counterproductive when it is sustained at low levels for decades without resolution.

This is the evolutionary logic of inflammaging: a mechanism calibrated for acute bacterial defense operating in a chronic, sterile, low-grade register for which evolution had no corrective pressure. The clinician's task is to compensate for what evolution did not address. That means supporting mitophagy, reducing mTOR-driven suppression of autophagy, maintaining metabolic health to minimize mitochondrial ROS overproduction, sustaining hormonal environments that support mitochondrial biogenesis, and, where evidence warrants, considering pharmacological modulation of specific inflammatory nodes like NLRP3 and cGAS-STING.

The longevity program at Healthspan's Longevity Optimization integrates many of these levers into a supervised clinical framework, because no single intervention addresses the full complexity of the mitochondria inflammation mechanism. The biology is convergent; the clinical response must be equally so.

Conclusion: The Bacterium That Shapes How We Age

Two billion years after an ancient bacterium took up residence inside a larger cell, its molecular descendants continue to shape the immunological experience of aging. The mitochondria inflammation mechanism, from the cGAS-STING pathway activated by leaked mitochondrial DNA, to the NLRP3 inflammasome triggered by cardiolipin and oxidized nucleic acids, to the formyl peptide receptors responding to N-formyl fragments, represents one of the most deeply conserved and consequential axes of biology. It is not a disease mechanism in the conventional sense. It is the accumulated cost of carrying a bacterial genome in every cell, managed well in youth, increasingly poorly in age.

Understanding this mechanism does not make aging optional. But it does make inflammaging targetable in ways that were not possible a decade ago. Exercise, mitophagy-enhancing compounds, mTOR modulation, hormonal support, metabolic optimization, and emerging cGAS-STING antagonists all converge on the same fundamental goal: keeping mitochondria intact and functional so they do not transmit a false bacterial distress signal to the immune system. The ancient symbiont inside every cell has served humanity extraordinarily well. The task of longevity medicine, in part, is ensuring it continues to do so for as long as possible.